Treatment of hormone-refractory prostate cancer

Details Treatment of hormone-refractory prostate cancer Treatment of hormone-refractory prostate cancer

A - Human Necessities

61

K

A61K 31/138 (2006.01) A61K 31/122 (2006.01) A61K 31/395 (2006.01) A61K 31/573 (2006.01) A61P 35/00 (2006.01)

Patent

CA 2429139

A proportion of patients with hormone-refractory prostate cancer have greater survival times by treatment with DPPE, mitoxantrone and prednisone than patients receiving mitoxantrone and prednisone alone.

Affiliated with

Also associated with

Rating

Treatment of hormone-refractory prostate cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of hormone-refractory prostate cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of hormone-refractory prostate cancer will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-2046223